Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.…
Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Immuron (NASDAQ: IMRN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 0.8998 USD on 20 November 2026, down 44.1% over 52 weeks. Its 52-week range is 0.6770 USD to 1.990 USD: the price is 54.8% below the high and 32.9% above the low.
Its market capitalisation is 7.26M USD.
Immuron reports return on equity of -33.0%, an operating margin of -46.2% and revenue up 7.2% year over year.
It holds more cash than debt, a net cash position of 8.83M AUD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 2.505 USD is 178.4% above the current price.